Industry News
Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size.
Novo Nordisk announced on August 10 that the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg …
Novo Nordisk provides a development update on two new investigational drugs for the bleeding disorders community.
The company’s ultra fastacting recombinant factor VIIa is progressing to a phase 3 trial after the successful completion of a phase 2 safety, pharmacokinetics and efficacy trial; the phase 3 trial is currently being designed. A phase 3 trial for the factor XIII drug was recently been completed and showed …
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
Pfizer is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval for the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is an injectable recombinant factor VIII product previously approved by …
BioRx President Phil Rielly Wins Ernst & Young Entrepreneur of the Year® Award
(Cincinnati, Ohio) July 20, 2010 – Philip Rielly, President and Co-founder of specialty pharmacy BioRx LLC, has received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the Healthcare category in South Central Ohio and Kentucky. …
Winners announced for 2010 BioRx Educational Scholarships
News Release
June 21, 2010 (Cincinnati, Ohio) BioRx, a specialty pharmacy, and Hemophilia of North Carolina, a non-profit organization that assists and educates persons affected by bleeding disorders, announce the winners of the 2010 BioRx Educational Scholarships. Each of the winners receives a $2,000 …
Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients
Buenos Aires, Argentina, (July 13, 2010) – Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Hemophilia. …
Novo Nordisk re-initiates phase 3 development of liraglutide for obesity
Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity.Following the US approval of Victoza® for the treatment of type 2 diabetes, Novo Nordisk has been in dialogue…
BioRX Announces New National Director of Operations
Randy Broyles, RPh has joined BioRx as National Director of Operations. See more…Randy Boyles
CSL Behring Awards Grassroots Advocacy Grants To Patient Organizations In Maryland, California, Tennessee, Montana
CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $50,000 to four patient organizations through the Local Empowerment for Advocacy Development…
CSL Behring Receives Canadian Notice of Compliance for Berinert®
CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of mode…
